AMP:MILAmplifon SpA Analysis
Data as of 2026-03-15 - not real-time
€10.52
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Amplifon is trading well below its 20‑day (12.17), 50‑day (13.08) and 200‑day (15.41) moving averages, with the price at €10.52 hovering just above the identified support of €10.15. Momentum indicators are deeply bearish – the RSI sits at 25.9, the MACD line is negative (-0.83) and its histogram remains in the red, and the trend direction is flagged as bearish. Volatility is elevated at nearly 49% over the past 30 days, and the recent max drawdown exceeds 51%, underscoring short‑term price risk.
Fundamentally, the stock appears undervalued: its trailing PE of 20.6 is well below the industry average of 26.2, and the forward PE contracts to 11.4, suggesting a sizable upside of roughly 48% versus the current price. The dividend yield of 2.76% is attractive, but the high debt‑to‑equity ratio of 195% and negligible operating cash flow raise concerns about the sustainability of payouts. With a modest beta (0.28) and a “Greed” market sentiment (fear‑greed index 72.9), the stock sits at a crossroads between technical weakness and valuation appeal.
Fundamentally, the stock appears undervalued: its trailing PE of 20.6 is well below the industry average of 26.2, and the forward PE contracts to 11.4, suggesting a sizable upside of roughly 48% versus the current price. The dividend yield of 2.76% is attractive, but the high debt‑to‑equity ratio of 195% and negligible operating cash flow raise concerns about the sustainability of payouts. With a modest beta (0.28) and a “Greed” market sentiment (fear‑greed index 72.9), the stock sits at a crossroads between technical weakness and valuation appeal.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Bearish momentum (RSI 25, MACD negative)
- Price near technical support
- High short‑term volatility
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Undervalued relative to peers (PE below industry)
- Attractive dividend yield
- Elevated leverage and weak cash generation
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Significant upside potential (≈48% upside)
- Stable demand in hearing‑care market
- Digital platform initiatives (Ampli‑care, Amplifon App) driving future growth
Key Metrics & Analysis
Financial Health
Revenue Growth-1.90%
Profit Margin3.81%
P/E Ratio20.6
ROE8.61%
Debt/Equity195.11
P/B Ratio2.4
Industry P/E26.2
Technical Analysis
TrendBearish
RSI25.9
Support€10.15
Resistance€13.79
MA 20€12.17
MA 50€13.08
MA 200€15.41
MACDBearish
VolumeIncreasing
Fear & Greed Index72.88
Valuation
Target Price€15.64
Upside/Downside48.68%
GradeUndervalued
TypeValue
Dividend Yield2.76%
Risk Assessment
Beta0.28
Volatility48.69%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.